Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
Income from Continuing Operations
Interpace Biosciences Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Interpace Biosciences Inc
OTC:IDXG
|
Income from Continuing Operations
$1.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Income from Continuing Operations
$1.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Income from Continuing Operations
$870m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
CVS Health Corp
NYSE:CVS
|
Income from Continuing Operations
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
Cigna Corp
NYSE:CI
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Income from Continuing Operations
$400.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
See Also
What is Interpace Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
1.1m
USD
Based on the financial report for Dec 31, 2023, Interpace Biosciences Inc's Income from Continuing Operations amounts to 1.1m USD.